99
Participants
Start Date
March 2, 2015
Primary Completion Date
August 13, 2019
Study Completion Date
August 13, 2019
Radium-223 dichloride (Xofigo, BAY88-8223)
Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of National Institute of Standards and Technology \[NIST\] update)
Placebo (saline)
Up to 6 cycles of saline injection
Background hormonal therapy
Prescribed by PI and was provided as long as patient can tolerate treatment. It must be prescribed as per local label in country participating.
Dublin
Copenhagen
Herlev
Linz
Aarau
Innsbruck
Taipei
Prague
A Coruña
Annapolis
Madrid
Madrid
Madrid
Málaga
Seville
Daegu
Essen
Ann Arbor
Pontiac
Angers
Busan
Zaragoza
Cedar Rapids
Bonn
St Louis
Tel Aviv
Tübingen
Houston
Aurora
La Jolla
Saint-Cloud
Bakersfield
Singapore
Afula
Haifa
Kfar Saba
Ramat Gan
Ẕerifin
Jerusalem
Jerusalem
New Haven
Pittsburgh
Winnipeg
London
Newmarket
Toronto
Ostrava
Helsinki
Tampere
Kowloon
Cork
Incheon
Nieuwegein
Zwolle
Oslo
Bialystok
Gdynia
Warsaw
Seoul
Seoul
Seoul
L'Hospitalet de Llobregat
Barcelona
Barcelona
Plymouth
Merseyside
Northwood
Nottingham
Taunton
Cottingham
Sheffield
Lead Sponsor
Bayer
INDUSTRY